當(dāng)前位置：首頁 JCRQ2 期刊介紹(非官網(wǎng))

Journal Of Cardiovascular PharmacologySCIE

國際簡稱：J CARDIOVASC PHARM 參考譯名：心血管藥理學(xué)雜志

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q2

基本信息：: ISSN：0160-2446; E-ISSN：1533-4023; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：UNITED STATES; 出版商：Lippincott Williams and Wilkins Ltd.; 出版語言：English; 出版周期：Monthly; 出版年份：1979; 研究方向：心血管系統(tǒng)-醫(yī)學(xué)

評價信息：: 影響因子：2.6; H-index：91; CiteScore指數(shù)：5.1; SJR指數(shù)：0.61; SNIP指數(shù)：0.504

發(fā)文數(shù)據(jù)：: Gold OA文章占比：14.35%; 研究類文章占比：75.27%; 年發(fā)文量：93; 自引率：0.0333...; 開源占比：0.1245; 出版撤稿占比：0.0163...; 出版國人文章占比：0.31; OA被引用占比：0.0977...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介Journal Of Cardiovascular Pharmacology期刊介紹

Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias.

Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.

期刊簡介Journal Of Cardiovascular Pharmacology期刊介紹

《Journal Of Cardiovascular Pharmacology》自1979出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個領(lǐng)域的原創(chuàng)研究提供一個展示平臺，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時報道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計審稿時間：約1月
醫(yī)學(xué)
CARDIAC & CARDIOVASCULAR SYSTEMS
SCIE
中科院4區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Journal Of Cardiovascular Pharmacology Cite Score數(shù)據(jù)

CiteScore：5.1
SJR：0.61
SNIP：0.504

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Cardiology and Cardiovascular Medicine	Q2	114 / 387	70%
大類：Medicine 小類：Pharmacology	Q2	150 / 313	52%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻(xiàn)計量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評價。

歷年Cite Score趨勢圖

中科院SCI分區(qū)Journal Of Cardiovascular Pharmacology 中科院分區(qū)

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	4區(qū)	CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統(tǒng) PHARMACOLOGY & PHARMACY 藥學(xué)	4區(qū) 4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計量學(xué)方法對國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級劃分的期刊評價標(biāo)準(zhǔn)。它為我國科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評價國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個層次，類似于“優(yōu)、良、及格”等。最開始，這個分區(qū)只是為了方便圖書管理及圖書情報領(lǐng)域的研究和期刊評估。之后中科院分區(qū)逐步發(fā)展成為了一種評價學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢圖

JCR分區(qū)Journal Of Cardiovascular Pharmacology JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	84 / 220	62%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q2	173 / 354	51.3%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	88 / 220	60.23%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q2	168 / 354	52.68%

JCR分區(qū)的優(yōu)勢在于它可以幫助讀者對學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評估。不同學(xué)科的文章引用量可能存在較大的差異，此時單獨(dú)依靠影響因子(IF)評價期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計

國家/地區(qū)數(shù)量
CHINA MAINLAND149
USA90
Italy23
Japan20
GERMANY (FED REP GER)19
Brazil11
France11
Canada10
Netherlands10
England9

本刊中國學(xué)者近年發(fā)表論文

1、Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus With Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials
Author: Yang, Shuai; Shen, Wen; Zhang, Hong-zhou; Wang, Chen-xi; Yu, Wan-qian; Wu, Qing-hua

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2023; Vol. 81, Issue 1, pp. 55-62. DOI: 10.1097/FJC.0000000000001364
2、Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Author: Xie, Yafei; Wei, Yujie; Li, Dan; Pu, Jie; Ding, Hong; Zhang, Xiaowei

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2023; Vol. 81, Issue 1, pp. 4-14. DOI: 10.1097/FJC.0000000000001380
3、Effects of Recombinant Human Brain Natriuretic Peptide on Atrial Fibrillation After Coronary Artery Bypass Grafting
Author: Wei, Yangyan; Zhang, Qian; Chi, Honghui; Wang, Ziyao; Chang, Qing

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2023; Vol. 81, Issue 1, pp. 63-69. DOI: 10.1097/FJC.0000000000001370
4、Salidroside Regulates Mitochondrial Homeostasis After Polarization of RAW264.7 Macrophages
Author: Wang, Xiu-Long; Sun, Rui-Xiang; Li, Dong-Xu; Chen, Zhi-Gang; Li, Xue-Fang; Sun, Si-Yu; Lin, Fei; Zhao, Guo-An

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2023; Vol. 81, Issue 1, pp. 85-92. DOI: 10.1097/FJC.0000000000001362
5、Silencing of Long Noncoding RNA TUG1 Ameliorates Atherosclerosis-Induced Myocardial Injury by Upregulating microRNA-30b-3p and Downregulating Brd4
Author: Li, De-long; Zheng, Bin-bin; Zeng, Xin; Li, Jiahua; Dai, Ruo-zhu

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2023; Vol. 81, Issue 1, pp. 45-54. DOI: 10.1097/FJC.0000000000001367
6、Feedback Interaction Between Apelin and Endoplasmic Reticulum Stress in the Rat Myocardium
Author: Jin, Sheng; Wang, Yipu; Ma, Liuchang; Zhang, Jiaqi; Huang, Panna; Zhang, Haozhe; Liu, Xinxia; Wu, Yuming; Wang, Xiaoning; Teng, Xu

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2023; Vol. 81, Issue 1, pp. 21-34. DOI: 10.1097/FJC.0000000000001369
7、Renal Safety of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials
Author: Zheng, Shaohua; Zhang, Yujiao; Gu, Lei; Ma, Kai; Wang, Xuehan; Hou, Yinglong; Zhang, Fenglei; Gao, Mei

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2023; Vol. 81, Issue 2, pp. 93-103. DOI: 10.1097/FJC.0000000000001379
8、Effect of Dexmedetomidine on Cardiac Surgery Patients
Author: Xiao, Man; Jiang, Chong-Fa; Gao, Qin; Pan, Jue; Zhang, Hong; Wu, Sheng-Nan; Dou, Mao-Sen

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2023; Vol. 81, Issue 2, pp. 104-113. DOI: 10.1097/FJC.0000000000001384